Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Clinical Trials
521
Trial Phases
6 Phases
Drug Approvals
9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (417 trials with phase data)• Click on a phase to view related trials
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT07047820
- Locations
- 🇺🇸
CVS Health, Woonsocket, Rhode Island, United States
A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT07019064
- Locations
- 🇺🇸
Trialmed formerly PPD, Austin Clinic, Austin, Texas, United States
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT06962800
- Locations
- 🇺🇸
James J Peters Veterans Administration Medical Center - NAVREF - PPDS, Bronx, New York, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac, Michigan, United States
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 255
- Registration Number
- NCT06953583
- Locations
- 🇺🇸
UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California, United States
🇺🇸Norman Fixel Institute for Neurological Diseases UF Health, Gainesville, Florida, United States
🇺🇸USF Health Morsani College of Medicine Department of Neurology, Tampa, Florida, United States
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 454
- Registration Number
- NCT06935357
- Locations
- 🇺🇸
Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸Kidney & Hypertension Center - Apple Valley, Apple Valley, California, United States
🇺🇸FOMAT Medical Research - FOMAT - PPDS, Oxnard, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 100
- Next
News
Ionis Pharmaceuticals Reports Strong Q2 2025 Results, Raises Guidance on TRYNGOLZA Success
Ionis Pharmaceuticals delivered $19 million in net product sales for TRYNGOLZA in Q2 2025, driving a doubling of total revenue to $452 million compared to the same period last year.
Roche Launches Clinical Trial for Trontinemab to Prevent Alzheimer's Disease
Roche announced plans to test Trontinemab, an experimental drug designed to delay or prevent Alzheimer's disease symptoms in at-risk individuals.
Biogen's Zurzuvae Receives EMA Panel Recommendation for Postpartum Depression Treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization for Biogen's ZURZUVAE (zuranolone) for treating postpartum depression in adults following childbirth.
IXICO Secures Full Data Rights to Landmark Bio-Hermes-002 Alzheimer's Study Through Strategic GAP Partnership
IXICO has deepened its collaboration with the Global Alzheimer's Platform Foundation through an agreement securing full data usage rights to the Bio-Hermes-002 study, one of the most prominent global studies in Alzheimer's disease research.
FDA Appoints Biotech Veteran George Tidmarsh to Lead Drug Regulation Center Amid Agency Restructuring
The FDA has appointed Dr. George Tidmarsh, a former pharmaceutical executive and cancer specialist, to direct the Center for Drug Evaluation and Research, the agency's largest division responsible for reviewing drug safety and effectiveness.
Harrow Secures Exclusive US Rights to Samsung Bioepis Ophthalmology Biosimilars Portfolio
Harrow has entered into a partnership with Samsung Bioepis to gain exclusive US commercial rights to two FDA-approved ophthalmology biosimilars, BYOOVIZ and OPUVIZ, following Biogen's termination of its commercialization agreement.
Vor Bio Appoints Telitacicept Development Expert Dr. Qing Zuraw as Chief Development Officer
Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in autoimmune disease clinical development.
Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.
NeuroSense's PrimeC Shows 33% Reduction in ALS Disease Progression in Phase 2b Trial
NeuroSense Therapeutics' PrimeC demonstrated a statistically significant 33% reduction in ALS disease progression (p=0.007) and 58% improvement in survival rates in its Phase 2b PARADIGM trial.
Brenig Therapeutics Appoints New Leadership and Expands Parkinson's Disease Pipeline with NLRP3 Inhibitor Acquisition
Brenig Therapeutics appointed David L. Lucchino as CEO and Tien Dam, M.D., as Chief Medical Officer to advance its neurodegenerative disease pipeline.